DK1533292T3 - Dibenzylaminforbindelse og medicinsk anvendelse deraf - Google Patents

Dibenzylaminforbindelse og medicinsk anvendelse deraf

Info

Publication number: DK1533292T3
Authority: DK; Denmark
Prior art keywords: alkyl group; hydrogen atom; dibenzylamine compound; medical use; halogen atom
Prior art date: 2002-08-30

Application number

DK03791414T

Other languages

English (en)

Inventor

Kimiya Maeda

Hironobu Nagamori

Hiroshi Nakamura

Hisashi Shinkai

Yasunori Suzuki

Daisuke Takahashi

Toshio Taniguchi

Original Assignee

Japan Tobacco Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-30

Filing date

2003-08-29

Publication date

2007-06-04

2003-08-29 Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc

2007-06-04 Application granted granted Critical

2007-06-04 Publication of DK1533292T3 publication Critical patent/DK1533292T3/da

Links

-1 Dibenzylamine compound Chemical class 0.000 title abstract 2
125000005843 halogen group Chemical group 0.000 abstract 3
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
125000000623 heterocyclic group Chemical group 0.000 abstract 2
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 abstract 1
206010003210 Arteriosclerosis Diseases 0.000 abstract 1
102100037637 Cholesteryl ester transfer protein Human genes 0.000 abstract 1
101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 abstract 1
208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
125000004432 carbon atom Chemical group C* 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
230000000069 prophylactic effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Solid Fuels And Fuel-Associated Substances (AREA)

DK03791414T 2002-08-30 2003-08-29 Dibenzylaminforbindelse og medicinsk anvendelse deraf DK1533292T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2002255604		2002-08-30
JP2003107161		2003-04-10
PCT/JP2003/011041 WO2004020393A1 (ja)	2002-08-30	2003-08-29	ジベンジルアミン化合物及びその医薬用途

Publications (1)

Publication Number	Publication Date
DK1533292T3 true DK1533292T3 (da)	2007-06-04

Family

ID=31980551

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK03791414T DK1533292T3 (da)	2002-08-30	2003-08-29	Dibenzylaminforbindelse og medicinsk anvendelse deraf

Country Status (24)

Country	Link
US (2)	US7332514B2 (da)
EP (2)	EP1829858A3 (da)
KR (1)	KR100634195B1 (da)
CN (1)	CN1289467C (da)
AT (1)	ATE353870T1 (da)
AU (1)	AU2003261826B2 (da)
BR (1)	BR0306208A (da)
CA (1)	CA2464846C (da)
CY (1)	CY1106425T1 (da)
CZ (1)	CZ2004627A3 (da)
DE (1)	DE60311821T2 (da)
DK (1)	DK1533292T3 (da)
ES (1)	ES2277142T3 (da)
IL (2)	IL161559A0 (da)
MX (1)	MXPA04005350A (da)
NO (1)	NO328886B1 (da)
NZ (1)	NZ532494A (da)
PT (1)	PT1533292E (da)
RU (1)	RU2293078C2 (da)
SI (1)	SI1533292T1 (da)
SK (1)	SK2332004A3 (da)
TR (1)	TR200401413T1 (da)
WO (1)	WO2004020393A1 (da)
ZA (1)	ZA200403137B (da)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040048780A1 (en) *	2000-05-10	2004-03-11	The Trustees Of Columbia University In The City Of New York	Method for treating and preventing cardiac arrhythmia
US8022058B2 (en)	2000-05-10	2011-09-20	The Trustees Of Columbia University In The City Of New York	Agents for preventing and treating disorders involving modulation of the RyR receptors
US20060293266A1 (en) *	2000-05-10	2006-12-28	The Trustees Of Columbia	Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US7393652B2 (en) *	2000-05-10	2008-07-01	The Trustees Of Columbia University In The City Of New York	Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US20040229781A1 (en) *	2000-05-10	2004-11-18	Marks Andrew Robert	Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US7718644B2 (en) *	2004-01-22	2010-05-18	The Trustees Of Columbia University In The City Of New York	Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US6489125B1 (en) *	2000-05-10	2002-12-03	The Trustees Of Columbia University In The City Of New York	Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US7312044B2 (en)	2003-03-07	2007-12-25	The Trustees Of Columbia University In The City Of New York	Type 1 ryanodine receptor-based methods
US7879840B2 (en) *	2005-08-25	2011-02-01	The Trustees Of Columbia University In The City Of New York	Agents for preventing and treating disorders involving modulation of the RyR receptors
US7332514B2 (en) *	2002-08-30	2008-02-19	Japan Tobacco Inc.	Dibenzylamine compound and medicinal use thereof
US7544678B2 (en) *	2002-11-05	2009-06-09	The Trustees Of Columbia University In The City Of New York	Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
AU2008201550B2 (en) *	2003-09-26	2011-02-10	Japan Tobacco Inc.	Method of inhibiting remnant lipoprotein production
MXPA06003357A (es) *	2003-09-26	2006-06-08	Japan Tobacco Inc	Metodo para inhibir la produccion de lipoproteina remanente.
DE602004023100D1 (de)	2003-10-08	2009-10-22	Lilly Co Eli	Verbindungen und verfahren zur behandlung von dyslipidemie
US8710045B2 (en) *	2004-01-22	2014-04-29	The Trustees Of Columbia University In The City Of New York	Agents for preventing and treating disorders involving modulation of the ryanodine receptors
JP4587685B2 (ja) *	2004-03-23	2010-11-24	セントラル硝子株式会社	３−ホルミル−５−トリフルオロメチルベンゾニトリル誘導体とその製造方法
JP2007530550A (ja) *	2004-03-26	2007-11-01	イーライリリーアンドカンパニー	異脂肪血症を治療するための化合物および方法
CA2562082C (en)	2004-04-13	2013-06-25	Merck & Co., Inc.	Cetp inhibitors for the treatment and prevention of atherosclerosis
EA200700119A1 (ru)	2004-06-24	2007-10-26	Эли Лилли Энд Компани	Соединения и способы лечения дислипидемии
AU2005268893B2 (en) *	2004-08-05	2011-10-13	F. Hoffmann-La Roche Ag	Indole, indazole or indoline derivatives
WO2007075194A1 (en)	2005-12-28	2007-07-05	Reddy Us Therapeutics, Inc.	Selective benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors
CA2605214C (en)	2004-12-31	2016-07-12	Reddy Us Therapeutics, Inc.	Benzylamine derivatives as cetp inhibitors
US8604055B2 (en) *	2004-12-31	2013-12-10	Dr. Reddy's Laboratories Ltd.	Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
WO2006082518A1 (en)	2005-02-03	2006-08-10	Pfizer Products Inc.	Pharmaceutical compositions with enhanced performance
WO2006098394A1 (ja) *	2005-03-14	2006-09-21	Japan Tobacco Inc.	脂質吸収抑制方法および脂質吸収抑制剤
US7704990B2 (en) *	2005-08-25	2010-04-27	The Trustees Of Columbia University In The City Of New York	Agents for preventing and treating disorders involving modulation of the RyR receptors
JP2009513573A (ja) *	2005-09-30	2009-04-02	メルクエンドカムパニーインコーポレーテッド	コレステリルエステル転送蛋白阻害剤
CA2625988A1 (en) *	2005-10-19	2007-04-26	Merck & Co., Inc.	Cetp inhibitors
AR058605A1 (es) *	2005-12-22	2008-02-13	Takeda Pharmaceutical	Preparacion solida
KR20080086917A (ko) *	2005-12-29	2008-09-26	노파르티스 아게	콜레스테릴 에스테르 전달 단백질 (ｃｅｔｐ) 억제제로서의피리디닐 아민 유도체
UY30118A1 (es) *	2006-01-31	2007-06-29	Tanabe Seiyaku Co	Compueto amina trisustituido
UY30117A1 (es)	2006-01-31	2007-06-29	Tanabe Seiyaku Co	Compuesto amina trisustituido
US7572823B2 (en) *	2006-02-07	2009-08-11	Hoffmann-La Roche Inc.	Heteroaryl carboxamide compounds
WO2007092642A2 (en) *	2006-02-09	2007-08-16	Merck & Co., Inc.	Polymer formulations of cetp inhibitors
US8383660B2 (en)	2006-03-10	2013-02-26	Pfizer Inc.	Dibenzyl amine compounds and derivatives
US7919506B2 (en)	2006-03-10	2011-04-05	Pfizer Inc.	Dibenzyl amine compounds and derivatives
UY30244A1 (es)	2006-03-30	2007-11-30	Tanabe Seiyaku Co	Un proceso para preparar derivados de tetrahidroquinolina
GB0609268D0 (en) *	2006-05-10	2006-06-21	Novartis Ag	Organic compounds
US8232403B2 (en) *	2006-05-10	2012-07-31	Novartis Ag	Bicyclic derivatives as CETP inhibitors
RU2008148600A (ru) *	2006-05-11	2010-06-20	Новартис АГ (CH)	Производные бензиламина в качестве ингибиторов сетр
US8022217B2 (en)	2006-07-31	2011-09-20	Cadila Healthcare Limited	Compounds suitable as modulators of HDL
KR100821688B1 (ko)	2006-08-10	2008-04-11	(주)유케이케미팜	암로디핀 라셈화물의 입체이성질체의 분리방법과 그의친수성 약물 및 그의 제조방법
US7750019B2 (en)	2006-08-11	2010-07-06	Kowa Company, Ltd.	Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
US7790737B2 (en)	2007-03-13	2010-09-07	Kowa Company, Ltd.	Substituted pyrimidine compounds and their utility as CETP inhibitors
HUE024898T2 (en)	2007-04-13	2016-02-29	Kowa Co	New pyrimidine compound with dibenzylamine structure and drug containing compound
JP4846769B2 (ja) *	2007-07-30	2011-12-28	田辺三菱製薬株式会社	医薬組成物
JP4834699B2 (ja) *	2007-07-30	2011-12-14	田辺三菱製薬株式会社	医薬組成物
JP5319457B2 (ja) *	2008-08-25	2013-10-16	興和株式会社	新規なジベンジルアミン構造を有するピリミジン化合物及びこれを含有する医薬
CN102300839B (zh) *	2008-11-28	2014-12-10	兴和株式会社	反式-{4-[(烷基氨基)甲基]环己基}乙酸酯的制备方法
TWI450896B (zh)	2009-06-30	2014-09-01	Lilly Co Eli	反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
SG10201605304VA (en) *	2011-07-08	2016-08-30	Novartis Ag	Method of treating atherosclerosis in high triglyceride subjects
EP2744803A2 (en)	2011-08-18	2014-06-25	Dr. Reddy's Laboratories Ltd.	Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors
MX352074B (es)	2011-09-27	2017-11-08	Dr Reddys Laboratories Ltd	Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.
WO2014192903A1 (ja)	2013-05-31	2014-12-04	興和株式会社	ジベンジルアミン構造を有するピリミジン化合物の新規形態
KR102431436B1 (ko)	2014-08-29	2022-08-10	테스 파마 에스.알.엘.	α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
EP3490579B1 (en)	2016-07-27	2025-09-10	Hartis-Pharma SA	Therapeutic combinations to treat red blood cell disorders

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3576830A (en) *	1966-08-12	1971-04-27	Sumitomo Chemical Co	Amides containing sulfur
US4064125A (en) *	1976-10-29	1977-12-20	E. R. Squibb And Sons, Inc.	Substituted amides having antiinflammatory activity
US4473579A (en) *	1982-01-26	1984-09-25	American Cyanamid Company	Antiatherosclerotic tetrasubstituted ureas and thioureas
US4623662A (en) *	1985-05-23	1986-11-18	American Cyanamid Company	Antiatherosclerotic ureas and thioureas
US5446207A (en)	1993-09-01	1995-08-29	Harbor Branch Oceanographic Institution, Inc.	Anti-dyslipidemic agents
FI964342A7 (fi)	1994-04-29	1996-10-28	Vertex Pharma	Halogeenimetyyliamideja IL-1beta-proteaasi-inhibiittoreina
KR970706242A (ko)	1994-10-04	1997-11-03	후지야마 아키라	우레아 유도체 및 ACAT-억제제로서 그의 용도(Urea derivatives and their use as ACAT-inhibitors)
US5834514A (en) *	1995-05-30	1998-11-10	Vertex Pharmaceuticals, Incorporated	Halomethyl amides as IL-1β protease inhibitors
GB9526560D0 (en)	1995-12-27	1996-02-28	Bayer Ag	Use of 2-Amino-Heterocycles
AR008789A1 (es)	1996-07-31	2000-02-23	Bayer Corp	Piridinas y bifenilos substituidos
JP2894445B2 (ja) *	1997-02-12	1999-05-24	日本たばこ産業株式会社	Ｃｅｔｐ活性阻害剤として有効な化合物
WO1999018066A1 (en) *	1997-10-02	1999-04-15	Sankyo Company, Limited	Amidocarboxylic acid derivatives
JP2002505318A (ja)	1998-03-05	2002-02-19	アゴーロン・ファーマシューティカルズ・インコーポレイテッド	非ペプチドＧｎＲＨ因子
SE9802209D0 (sv)	1998-06-22	1998-06-22	Astra Pharma Inc	Novel compounds
US6147090A (en)	1998-09-17	2000-11-14	Pfizer Inc.	4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en)	1998-09-17	2001-03-06	Pfizer Inc	4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
CA2345108A1 (en) *	1998-09-25	2000-04-06	Monsanto Company	Substituted n-aliphatic-n-aromatic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
JP3924124B2 (ja) *	1998-09-25	2007-06-06	ファルマシア・コーポレーション	コレステロールエステル輸送タンパク質活性阻害に有効な置換された多環アリールおよびヘテロアリール第三級ヘテロアルキルアミン
DE60023492T2 (de)	1999-05-17	2006-07-20	Novo Nordisk A/S	Glucagon antagonisten/inverse agonisten
UA73307C2 (uk)	1999-08-05	2005-07-15	Куміаі Кемікал Індастрі Ко., Лтд.	Похідна карбамату і фунгіцид сільськогосподарського/садівницького призначення
CO5271716A1 (es)	1999-11-30	2003-04-30	Pfizer Prod Inc	Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
BR0312452A (pt) *	2002-07-03	2005-04-19	Hoffmann La Roche	Composto; processo para a preparação de um composto; composição farmacêutica; uso de um composto; e método para o tratamento e/ou profilaxia de doenças que são moduladas por agonistas de ppar(alfa) e/ou ppar(gama)
US7332514B2 (en) *	2002-08-30	2008-02-19	Japan Tobacco Inc.	Dibenzylamine compound and medicinal use thereof

2003
- 2003-08-29 US US10/503,185 patent/US7332514B2/en not_active Expired - Fee Related
- 2003-08-29 DE DE60311821T patent/DE60311821T2/de not_active Expired - Lifetime
- 2003-08-29 PT PT03791414T patent/PT1533292E/pt unknown
- 2003-08-29 AT AT03791414T patent/ATE353870T1/de active
- 2003-08-29 AU AU2003261826A patent/AU2003261826B2/en not_active Ceased
- 2003-08-29 CA CA2464846A patent/CA2464846C/en not_active Expired - Fee Related
- 2003-08-29 EP EP07003011A patent/EP1829858A3/en not_active Withdrawn
- 2003-08-29 ES ES03791414T patent/ES2277142T3/es not_active Expired - Lifetime
- 2003-08-29 SI SI200330767T patent/SI1533292T1/sl unknown
- 2003-08-29 KR KR1020047010002A patent/KR100634195B1/ko not_active Expired - Fee Related
- 2003-08-29 RU RU2004119546/04A patent/RU2293078C2/ru not_active IP Right Cessation
- 2003-08-29 DK DK03791414T patent/DK1533292T3/da active
- 2003-08-29 WO PCT/JP2003/011041 patent/WO2004020393A1/ja not_active Ceased
- 2003-08-29 SK SK233-2004A patent/SK2332004A3/sk not_active Application Discontinuation
- 2003-08-29 NZ NZ532494A patent/NZ532494A/xx not_active IP Right Cessation
- 2003-08-29 TR TR2004/01413T patent/TR200401413T1/xx unknown
- 2003-08-29 EP EP03791414A patent/EP1533292B1/en not_active Expired - Lifetime
- 2003-08-29 BR BR0306208-2A patent/BR0306208A/pt not_active IP Right Cessation
- 2003-08-29 CN CNB038023830A patent/CN1289467C/zh not_active Expired - Fee Related
- 2003-08-29 CZ CZ2004627A patent/CZ2004627A3/cs unknown
- 2003-08-29 IL IL16155903A patent/IL161559A0/xx unknown
2004
- 2004-04-22 IL IL161559A patent/IL161559A/en not_active IP Right Cessation
- 2004-04-23 ZA ZA2004/03137A patent/ZA200403137B/en unknown
- 2004-06-03 MX MXPA04005350A patent/MXPA04005350A/es active IP Right Grant
- 2004-06-18 NO NO20042584A patent/NO328886B1/no not_active IP Right Cessation
2007
- 2007-03-30 CY CY20071100447T patent/CY1106425T1/el unknown
- 2007-11-13 US US11/939,359 patent/US7807701B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
KR20040075908A (ko)	2004-08-30
MXPA04005350A (es)	2004-09-27
RU2293078C2 (ru)	2007-02-10
RU2004119546A (ru)	2005-08-10
PT1533292E (pt)	2007-05-31
CN1617850A (zh)	2005-05-18
US20050059810A1 (en)	2005-03-17
AU2003261826A1 (en)	2004-03-19
EP1533292A1 (en)	2005-05-25
US7332514B2 (en)	2008-02-19
ZA200403137B (en)	2005-06-29
CN1289467C (zh)	2006-12-13
WO2004020393A1 (ja)	2004-03-11
EP1829858A3 (en)	2007-10-03
EP1533292A4 (en)	2005-11-02
DE60311821T2 (de)	2007-10-31
EP1829858A2 (en)	2007-09-05
CA2464846A1 (en)	2004-03-11
IL161559A (en)	2009-12-24
ATE353870T1 (de)	2007-03-15
AU2003261826B2 (en)	2006-02-02
CY1106425T1 (el)	2011-10-12
IL161559A0 (en)	2004-09-27
BR0306208A (pt)	2004-10-13
NO20042584L (no)	2004-06-18
ES2277142T3 (es)	2007-07-01
KR100634195B1 (ko)	2006-10-16
US20080146620A1 (en)	2008-06-19
EP1533292B1 (en)	2007-02-14
SI1533292T1 (sl)	2007-08-31
HK1077567A1 (en)	2006-04-13
US7807701B2 (en)	2010-10-05
DE60311821D1 (de)	2007-03-29
CZ2004627A3 (cs)	2004-10-13
NZ532494A (en)	2006-03-31
CA2464846C (en)	2010-04-06
NO328886B1 (no)	2010-06-07
TR200401413T1 (tr)	2005-06-21
SK2332004A3 (en)	2004-12-01

Publication	Publication Date	Title
DK1533292T3 (da)	2007-06-04	Dibenzylaminforbindelse og medicinsk anvendelse deraf
BR0315405A (pt)	2005-08-09	Compostos inibidores da integrase tricìclica pré-organizados
MX2009012283A (es)	2009-11-25	Derivado heterociclico que contiene nitrogeno que tiene actividad inhibitoria de 11beta-hidroxiesteroide-deshidrogenasa tipo 1.
CA2534024A1 (en)	2005-02-10	Novel compounds having inhibitory activity against sodium-dependant transporter
HUP0402376A2 (hu)	2005-02-28	Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények
NO20060219L (no)	2006-04-28	Forbindelser
TW200407309A (en)	2004-05-16	1,2-Azole derivatives
DK1382604T3 (da)	2006-04-18	Quinolinderivater med en azolylgruppe og quinazolinderivater
JO2791B1 (en)	2014-03-15	Acid secretion inhibitor
NO20065494L (no)	2006-12-19	Fuserte kinolinderivater og anvendelse derav
MY139887A (en)	2009-11-30	Tetrahydronaphthyridine derivatives and a process for preparing the same.
ATE154021T1 (de)	1997-06-15	N-cyclohexyl benzamide derivate, ihre herstellungen und therapeutischen anwendungen
TW200619212A (en)	2006-06-16	Morpholine derivatives
DK393486D0 (da)	1986-08-19	Dihydropyridin-derivater og fremgangsmaade til fremstilling deraf
IL160874A0 (en)	2004-08-31	4-imidazolin-2-one derivatives
TW200517387A (en)	2005-06-01	Compounds exhibiting thrombopoietin receptor agonism
ATE504572T1 (de)	2011-04-15	Derivate von aromatische heterocyclen enthaltende integraseinhibitoren
EA200401077A1 (ru)	2005-06-30	2-оксазоламины и их применение в качестве антагонистов рецептора 5-ht2b
ATE229538T1 (de)	2002-12-15	22r-hydroxycholesta-8,14-diene derivate zur hemmung der meiose
MY139258A (en)	2009-09-30	Carbamoyl-type benzofuran derivatives
EP1908752A4 (en)	2009-09-02	NEW 2-CHINOLO DERIVATIVES
HU9503718D0 (en)	1996-03-28	Serotoninergic abeo-ergoline derivatives
NO20053302D0 (no)	2005-07-05	Imidazolderivater med affinitet for alfa 2-reseptoraktivitet.
TW200508211A (en)	2005-03-01	2-naphthylimino-1,3-thiazine derivatives